# Sensei Biotherapeutics (SNSE) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/SNSE
## Company Profile
- Ticker: SNSE
- Exchange: NYSE
- Sector: Biopharma
- Location: United States
- Tags: Immunotherapy, Oncology
## Stock Data
- Close: 13.85 USD
- Market cap: 21598540.395 USD
- Last updated: 2026-06-15
## Business Overview
Sensei Biotherapeutics is an immuno-oncology company focused on activating the immune system against cancer. Its platform aims to create differentiated cancer treatments through immune modulation.
## Why The Stock Is Moving

Current closing-price context is not available for SNSE.

## Geographic Base

Headquartered in the United States and listed on NASDAQ, Sensei sits in specialty oncology biotechnology.

## Business Model

The company depends on clinical data, immune-mechanism validation, and the ability to build a durable cancer franchise.

## Landscape Position

Sensei is a catalyst-driven immuno-oncology name whose stock responds to early clinical and translational progress.

## Future Catalysts

- The cleaner way to frame Sensei Biotherapeutics right now is around its latest development priorities. The most useful line from the latest update is First patient dosed in Phase 1b/2 trial of PIKTOR in HR+/HER2- advanced breast cancer Topline Phase 2 data in patients with advanced endometrial cancer expected in second half.... That should keep the program at the center of the company narrative for now.

## Recent News
- 2026-05-15 11:30 EST — [Sensei Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/SNSE/sensei-biotherapeutics-reports-first-quarter-2026-financial-results-and-provides-corporate-update) — Source: Sensei Biotherapeutics
- 2026-05-05 11:30 EST — [Sensei Biotherapeutics Doses First Patient in Phase 1b/2 Trial of PIKTOR in HR+/HER2- Advanced Breast Cancer](https://biopharmsignal.com/news/SNSE/sensei-biotherapeutics-doses-first-patient-in-phase-1b-2-trial-of-piktor-in-hr-her2-advanced-breast-cancer) — Source: Sensei Biotherapeutics
- 2026-04-09 11:30 EST — [Sensei Biotherapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference](https://biopharmsignal.com/news/SNSE/sensei-biotherapeutics-to-present-at-the-25th-annual-needham-virtual-healthcare-conference) — Source: Sensei Biotherapeutics
- 2026-03-30 11:30 EST — [Sensei Biotherapeutics Reports Full Year 2025 Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/SNSE/sensei-biotherapeutics-reports-full-year-2025-financial-results-and-provides-corporate-update) — Source: Sensei Biotherapeutics
- 2026-03-17 10:00 EST — [Sensei Biotherapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/SNSE/sensei-biotherapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4) — Source: Sensei Biotherapeutics